With a view to create better awareness among the stakeholders. HEL Limited is conducting  a seminar on 'Using DOE in combination with parallel reactor platforms -QbD perspective as per US FDA regulation', on July 21 and 24, 2014 in Hyderabad and Bengaluru respectively. The seminar will be presented by Dr Jasbir Singh, CEO of HEL to tap the increase in competitive pressures from within the chemical process industry which demands more processes to be developed quickly, efficiently and with better performance ability.

The use of multiple (parallel) reactor platforms is becoming an established practice in the pharma industry, including the fulfillment of QbD regulation as laid out by the US Food and Drug Administration and more generally the specific use of DOE to direct experimental efforts and analyze data.

 This seminar will present key results from many different process development studies to illustrate the range of parallel reaction instruments available.

Examples will include those from organic and synthetic chemistry, as well as heterogeneous catalysis (including hydrogenation in flow reactors) and crystallisation studies will be used to describe the benefits of these techniques.

The seminar is designed to cater to all those involved in process and development, process optimisation, safe scale up , process engineering and R&D etc.



Please contact us at
marketing@helindia.com or register online at http://www.helgroup.com/india/seminar/